Search details
1.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Article
in English
| MEDLINE | ID: mdl-34081848
2.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet
; 389(10075): 1195-1205, 2017 03 25.
Article
in English
| MEDLINE | ID: mdl-28215665
3.
Rationale and design of the European Polyp Surveillance (EPoS) trials.
Endoscopy
; 48(6): 571-8, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27042931
4.
The impact of registration of clinical trials units: the UK experience.
Clin Trials
; 12(2): 166-73, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25475881
5.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet
; 382(9897): 1021-8, 2013 Sep 21.
Article
in English
| MEDLINE | ID: mdl-23871490
6.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med
; 353(16): 1659-72, 2005 Oct 20.
Article
in English
| MEDLINE | ID: mdl-16236737
7.
Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial.
JAMA Intern Med
; 176(7): 894-902, 2016 07 01.
Article
in English
| MEDLINE | ID: mdl-27214731
8.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
J Clin Oncol
; 34(10): 1034-42, 2016 Apr 01.
Article
in English
| MEDLINE | ID: mdl-26598744
Results
1 -
8
de 8
1
Next >
>>